Praxis Precision Medicines Q3 net loss widens

Praxis Precision Medicines

05/11/2025 13:11

Overview

Praxis reports Q3 net loss of $73.9 mln, with no collaboration revenue recognized

Operating expenses for Q3 rise to $78.4 mln, driven by increased R&D costs

Positive Phase 3 results for ulixacaltamide in essential tremor announced

Outlook

Company plans to accelerate relutrigine development with interim analysis in Q4 2025

Praxis expects to fund operations into 2028 with current cash and investments

Pre-NDA meeting for ulixacaltamide scheduled for Q4 2025

Result Drivers

Research and development expenses were $65.8 million for the three months ended September 30, 2025, compared to $41.9 million for the three months ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$3.36
Q3 Net Income
-$73.93 mln
Q3 Operating Expenses
$78.35 mln
Q3 Operating Income
-$78.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Praxis Precision Medicines Inc is $260.50, about 34.1% above its November 4 closing price of $171.75

Press Release: ID:nGNX1Frf3p

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)